The Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy (NCT02605785) is an active imaging study investigating tau burden in the brains of PSP patients using advanced PET imaging techniques. This study represents a critical effort to characterize the spatial distribution, magnitude, and clinical correlates of tau pathology in vivo, providing essential insights into disease pathogenesis and enabling the development of tau-targeted therapeutics.
Tau PET imaging has revolutionized our ability to visualize protein pathology in living patients. While historically limited to post-mortem neuropathological examination, modern tau PET tracers allow researchers and clinicians to observe the distribution and progression of tau deposits in the living brain. In PSP, this capability is particularly valuable because tau pathology is the defining neuropathological feature of the disease, and understanding its in vivo distribution is crucial for diagnosis, prognosis, and therapeutic development.
| Field | Value |
|---|---|
| NCT ID | NCT02605785 |
| Status | Recruiting |
| Condition | Progressive Supranuclear Palsy |
| Category | Neuroimaging / Tau PET |
| Study Type | Observational |
| Clinicaltrials.gov | NCT02605785 |
The study aims to comprehensively characterize tau burden in PSP patients through:
Quantifying Regional Tau Deposition: Measure tau PET signal across brain regions known to be affected in PSP, including the basal ganglia, brainstem, and cerebellar nuclei. This provides quantitative data on the magnitude of tau pathology in each region.
Characterizing Distribution Patterns: Define the spatial pattern of tau accumulation and compare it to known neuropathological patterns. The characteristic distribution of tau in PSP—affecting subcortical structures preferentially—distinguishes it from other tauopathies.
Correlating with Clinical Features: Establish relationships between tau burden and clinical manifestations, including:
Understanding Selective Neuronal Vulnerability: Investigate why specific neuronal populations are preferentially affected in PSP, using tau PET signal as a proxy for pathological burden.
Disease Progression Biomarkers: Establish whether tau PET signal correlates with disease progression rate, potentially enabling prediction of clinical course.
Therapeutic Target Validation: Provide data to support anti-tau therapeutic development by confirming target engagement and demonstrating that tau burden can be modulated.
Differential Diagnosis: Refine the diagnostic utility of tau PET for distinguishing PSP from other parkinsonian disorders, particularly Parkinson's disease, corticobasal syndrome, and multiple system atrophy.
Tau PET imaging has emerged as a critical tool for visualizing tau pathology in vivo. Unlike amyloid PET, where multiple FDA-approved tracers exist, tau PET tracers have been developed more recently and continue to evolve[@tau_pet_methods]. Key tracers used in PSP research include:
| Tracer | Target | Specificity | Status |
|---|---|---|---|
| [18F]PI-2620 | 4R tau | 4R-selective | Research |
| [18F]AV-1451 (Flortaucipir) | PHF tau | 3R/4R (prefers AD-type) | Research |
| [18F]MNI-958 | 4R tau | 4R-selective | Research |
| [18F]PM-PBB3 | PHF tau | 3R/4R | Research |
Traditional tau PET tracers like flortaucipir were developed for Alzheimer's disease and show high affinity for the paired helical filament (PHF) tau found in AD. However, PSP is characterized by different tau filament structures—predominantly straight filaments composed of 4-repeat (4R) tau isoforms. This structural difference limits the binding of some traditional tracers to PSP tau pathology[@4r_tracers].
Novel tracers specifically designed for 4R tauopathies, such as PI-2620, show improved binding to PSP tau deposits. These 4R-selective tracers bind to the distinct conformations of 4R tau filaments, enabling more sensitive detection of tau pathology in PSP patients.
Progressive Supranuclear Palsy is classified as a 4-repeat (4R) tauopathy, meaning it is characterized by accumulation of tau protein isoforms containing four microtubule-binding repeats. This distinguishes PSP from Alzheimer's disease, which involves both 3R and 4R tau, and from Pick's disease, which involves only 3R tau.
In PSP, 4R tau accumulates in specific anatomical regions[@psp_tau_distribution]:
Subcortical Structures:
Cortical Regions:
Cell Types Affected:
Emerging evidence suggests that tau aggregates in PSP may exist as distinct "strains" with different conformational properties[@tau_strains]. These strain differences may explain:
One of the most intriguing aspects of PSP is the selective vulnerability of specific neuronal populations. Certain brain regions and cell types are preferentially affected, while others are relatively spared. Tau PET imaging provides an in vivo window into this selective vulnerability[@selective_vulnerability].
This selective pattern suggests that intrinsic properties of vulnerable neurons—such as connectivity, metabolism, or protein homeostasis mechanisms—make them particularly susceptible to tau pathology.
The study employs standardized PET imaging protocols:
Image Acquisition:
Image Processing[@pet_quantification]:
Tau PET data are quantified using several approaches:
Choice of reference region is critical for PSP tau PET:
Cerebellar Gray Matter: Commonly used as reference, assuming relatively low tau pathology in this region. However, some tau accumulation occurs in cerebellar nuclei in PSP.
Cortical Reference: Some studies use mean cortical uptake as reference.
White Matter: Sometimes used, but may contain tau in PSP.
Tau PET imaging enables investigation of the relationship between tau pathology and clinical manifestations[@clinical_trials_taupet]:
Tau PET has significant diagnostic value in differentiating parkinsonian disorders[@diagnostic_accuracy]:
| Pattern | PSP | PD | MSA | CBS |
|---|---|---|---|---|
| Basal ganglia uptake | High | Low | Moderate | Moderate |
| Brainstem uptake | High | Low | Moderate | Variable |
| Cortical uptake | Low-moderate | Very low | Very low | Moderate |
| Pattern distinction | Subcortical | Minimal | Variable | Asymmetric |
Longitudinal tau PET studies demonstrate that tau burden increases over time in PSP[@longitudinal]. The rate of tau accumulation correlates with:
This progressive nature makes tau PET a promising biomarker for:
This imaging study contributes to understanding the spatial distribution of tau pathology in PSP, which is essential for:
Tau PET provides objective, in vivo evidence of tau pathology, supporting clinical diagnosis. This is particularly valuable in:
Tau PET enables non-invasive monitoring of disease progression:
The study supports anti-tau therapeutic development by:
Tau PET data illuminate disease mechanisms:
The molecular mechanisms underlying tau pathology in PSP involve:
Molecular Anatomic Imaging Analysis of Tau in PSP - ClinicalTrials.gov NCT02605785
Nichols M, et al. Tau PET imaging in 4R tauopathies. Neurology. 2020
Koga S, et al. PI-2620 as 4R tau selective PET tracer. Acta Neuropathol Commun. 2020
Kovacs GG, et al. Tau distribution in PSP brain. Handb Clin Neurol. 2018
Leuzy A, et al. Tau PET methodology in neurodegeneration. J Nucl Med. 2019
Declercq L, et al. Novel 4R-tau selective PET tracers. Eur J Nucl Med Mol Imaging. 2020
Buchsbaum MS, et al. PET quantification methods for tau imaging. J Cereb Blood Flow Metab. 2018
Bladowska J, et al. Tau biomarkers in PSP. J Neurol Sci. 2020
Pessoa D, et al. Tau PET and disease progression in PSP. Mov Disord. 2021
Matsukawa T, et al. Tau PET in clinical trials for PSP. CNS Drugs. 2022
Karantali E, et al. Tau PET diagnostic accuracy in parkinsonism. J Neurol. 2020
Fujita Y, et al. Brainstem tau pathology in PSP. Neuropathology. 2018
Chen L, et al. Basal ganglia involvement in PSP. J Neuroimaging. 2019
Matsumoto Y, et al. Subthalamic nucleus in PSP. Parkinsonism Relat Disord. 2018
Hatano T, et al. White matter tau pathology in PSP. Neurobiol Aging. 2020
Kovacs M, et al. Astrocytic tau pathology in PSP. Acta Neuropathol. 2020
Ikeda K, et al. Oligodendroglial tau in PSP. J Neuropathol Exp Neurol. 2020
Sanders ML, et al. Tau strain diversity in PSP. Nat Neurosci. 2022
Kaufman M, et al. Tau propagation in PSP. Brain Pathol. 2021
Walker L, et al. Longitudinal tau PET changes in PSP. Neurology. 2022
Villemagne VL, et al. Tau PET for therapy monitoring. Nat Rev Neurol. 2020
A significant challenge in tau PET imaging is the partial volume effect (PVE), which causes underestimation of tracer uptake in small structures due to the limited spatial resolution of PET. This is particularly problematic for PSP, where affected structures like the subthalamic nucleus are relatively small.
Solutions implemented in the study:
Many tau PET tracers show off-target binding to structures other than tau aggregates:
Common off-target sites:
Careful interpretation and correlation with clinical data helps distinguish true tau signal from off-target binding.
Different tau PET tracers show varying sensitivity to PSP tau pathology:
| Tracer | 4R Tau Sensitivity | Off-Target Issues | Clinical Utility |
|---|---|---|---|
| PI-2620 | High | Moderate (MAOs) | Good for PSP |
| Flortaucipir | Low-Moderate | Neuromelanin | Limited for PSP |
| PM-PBB3 | Moderate | Blood pool | Moderate for PSP |
| MNI-958 | High | Under investigation | Promising |
Ensuring reproducible results across scanner types, sites, and time points is critical:
Quality Control Measures:
Tau PET in AD shows distinct patterns from PSP:
| Feature | PSP | AD |
|---|---|---|
| Primary region | Subcortical (basal ganglia, brainstem) | Cortical (entorhinal, temporal) |
| Hippocampus | Relatively spared | Severely affected |
| Pattern | "Subcortical predominant" | "Cortical predominant" |
| Severity | Lower SUVR overall | Higher SUVR in affected regions |
Primary tau PET signal in PD is minimal, as PD is primarily an alpha-synucleinopathy:
CBS shares features with both PSP and AD:
MSA primarily involves alpha-synuclein in oligodendrocytes:
Next-generation tau PET tracers in development include:
More 4R-Selective Tracers:
Oligomer-Selective Tracers:
Faster-Clearance Tracers:
Combining tau PET with other imaging modalities provides complementary information:
MRI:
Amyloid PET:
FDG-PET:
Molecular Imaging:
Advanced quantification methods under development:
Machine Learning:
Graph Theory:
Tau PET is increasingly used in clinical trials:
Patient Selection:
Endpoint Measurement:
Disease-Modifying Assessment:
While primarily a research tool, tau PET has emerging clinical applications:
Differential Diagnosis:
Prognostication:
Monitoring:
Several factors limit widespread clinical use:
As the field advances, tau PET may become more clinically accessible:
The Molecular Anatomic Imaging Analysis of Tau in PSP represents a critical scientific endeavor that advances our understanding of tau pathology in living patients. By characterizing the in vivo distribution, magnitude, and clinical correlates of tau burden in PSP, this study provides essential insights into disease pathogenesis while supporting the development of tau-targeted therapeutics.
The study's findings will inform:
Tau PET imaging has transformed neurodegenerative disease research, and studies like this one continue to expand our capabilities for visualizing and understanding the pathological processes that underlie PSP and related disorders. The knowledge gained will ultimately contribute to developing effective treatments for these devastating conditions.